Item 8.01. Other Events.

Compliance with Minimum Bid Requirement

As previously disclosed in the Current Report on Form 8-K of Infinity Pharmaceuticals, Inc. (the "Company") filed with the Securities and Exchange Commission (the "Commission") on May 24, 2022, the Company received a notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that, for the prior thirty consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a period of 180 calendar days in which to regain compliance.

On August 24, 2022, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with the Minimum Bid Requirement and that this matter is now closed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses